The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
2021
-
Randomized Controlled Trial Multicenter Study
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. ⋯ In critically ill patients with Covid-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved outcomes, including survival. (REMAP-CAP ClinicalTrials.gov number, NCT02735707.).